NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $0.54 +0.07 (+15.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.53 -0.01 (-1.31%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rallybio Stock (NASDAQ:RLYB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rallybio alerts:Sign Up Key Stats Today's Range$0.43▼$0.5650-Day Range$0.29▼$0.5452-Week Range$0.22▼$1.30Volume913,345 shsAverage Volume8.41 million shsMarket Capitalization$22.26 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. Read More Rallybio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreRLYB MarketRank™: Rallybio scored higher than 36% of companies evaluated by MarketBeat, and ranked 716th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingRallybio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRallybio has received no research coverage in the past 90 days.Read more about Rallybio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.67% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently increased by 471.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.67% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently increased by 471.59%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Rallybio this week, compared to 1 article on an average week.Search Interest1 people have searched for RLYB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address RLYB Stock News HeadlinesEvercore ISI Remains a Hold on Rallybio (RLYB)July 16, 2025 | theglobeandmail.comRXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - NasdaqJuly 11, 2025 | nasdaq.comThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - MorningstarJuly 9, 2025 | morningstar.comMHere's Why Shares in Recursion Pharmaceuticals Surged TodayJuly 8, 2025 | finance.yahoo.comRallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | finance.yahoo.comRecursion to buy Rallybio’s ownership in jointly developed bone disorder drugJuly 8, 2025 | msn.comRallybio Sells REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | tipranks.comSee More Headlines RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $0.96 at the beginning of the year. Since then, RLYB shares have decreased by 44.3% and is now trading at $0.5350. How were Rallybio's earnings last quarter? Rallybio Corporation (NASDAQ:RLYB) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.21) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.21). The company had revenue of $0.21 million for the quarter. Rallybio had a negative trailing twelve-month return on equity of 72.31% and a negative net margin of 5,682.19%. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share. Who are Rallybio's major shareholders? Top institutional shareholders of Rallybio include Aberdeen Group plc (3.83%) and Canaan Partners XI LLC (2.26%). View institutional ownership trends. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rallybio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG). Company Calendar Last Earnings5/08/2025Today8/01/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Rallybio$10.00 High Price Target$15.00 Low Price Target$5.00 Potential Upside/Downside+1,769.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.78 million Net Margins-5,682.19% Pretax Margin-5,429.72% Return on Equity-72.31% Return on Assets-64.78% Debt Debt-to-Equity RatioN/A Current Ratio14.68 Quick Ratio14.68 Sales & Book Value Annual Sales$848 thousand Price / Sales26.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book0.36Miscellaneous Outstanding Shares41,614,000Free Float37,994,000Market Cap$22.26 million OptionableNot Optionable Beta-1.17 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:RLYB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.